fluphenazine has been researched along with Recrudescence in 94 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of oral fluphenazine with placebo for the treatment of schizophrenia." | 8.98 | Fluphenazine (oral) versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE; Sampson, SJ, 2018) |
| "Issues regarding the side effects of antipsychotic medication and the possible contribution of the environment to dose requirements led to a two-year controlled dosage study of maintenance antipsychotic medication and familial environment among recently discharged schizophrenic patients." | 6.66 | Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. ( Bartone, P; Carter, M; Cather, R; Cooley, SJ; DiBarry, AL; Hogarty, GE; Madonia, MJ; McEvoy, JP; Munetz, M; Ulrich, RF, 1988) |
| " The results suggest that lower doses of fluphenazine decanoate than those usually used may be effective in preventing psychotic relapse while keeping total cumulative dosage to a minimum." | 6.65 | Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. ( Kane, JM; Klein, DF; Nayak, D; Quitkin, F; Ramos-Lorenzi, JR; Rifkin, A; Sachar, EJ; Saraf, K, 1979) |
| "Fifty-three volunteer patients with recent-onset schizophrenia who had been clinically stabilized on a maintenance regimen of fluphenazine decanoate for a mean of 16." | 5.09 | Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. ( Aravagiri, M; Bartzokis, G; Fogelson, DL; Gitlin, M; Mintz, J; Nuechterlein, K; Subotnik, KL; Ventura, J, 2001) |
| "This study examined substance use among a group of 37 schizophrenia patients participating in a year-long fluphenazine decanoate (FD; Prolixin) dosage reduction study (Inderbitzin et al." | 5.08 | Substance use: a powerful predictor of relapse in schizophrenia. ( Inderbitzin, LB; Kasckow, JW; Scheller-Gilkey, G; Swofford, CD, 1996) |
| "This study evaluated the feasibility and impact of gradually reducing relatively high doses of fluphenazine decanoate by one-half for chronically impaired, poor inner-city patients with schizophrenia." | 5.07 | A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. ( Egan, GJ; Gloersen, BA; Inderbitzin, LB; Lewine, RR; Scheller-Gilkey, G; Swofford, CD; Vidanagama, BP; Waternaux, C, 1994) |
| "In an attempt to begin to establish minimum effective dosage requirements for the maintenance treatment of schizophrenia, we undertook a double-blind comparison of low-dose fluphenazine decanoate (1." | 5.05 | Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. ( Kane, JM; Ramos-Lorenzi, J; Reardon, G; Rifkin, A; Sarantakos, S; Schiebel, D; Woerner, M, 1983) |
| "Sixty patients meeting the criteria established for schizophrenia who attained a clinical plateau following hospital discharge were randomized to receive for one year either penfluridol, 20 to 160 mg orally once each week, or fluphenazine decanoate, 0." | 5.04 | Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics. ( Kane, J; Klein, DF; Quitkin, F; Ramos-Lorenzi, JR; Rifkin, A, 1978) |
| "To compare the effects of oral fluphenazine with placebo for the treatment of schizophrenia." | 4.98 | Fluphenazine (oral) versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE; Sampson, SJ, 2018) |
| " This study will present our own experience in the treatment of a pregnant woman suffering from schizophrenia, who was treated with ziprasidone for the duration of her pregnancy." | 3.75 | Pregnancy and atypical antipsychotics. ( Dadić-Hero, E; Knez, R; Medved, P; Petrić, D; Ruzić, K, 2009) |
| " We report the case of a 36 years old woman suffering from chronic schizophrenia and treated with flufenazine and olanzapine, who presented with series of generalised tonic-clonic seizures as the acute onset of recurrent malignant neuroleptic syndrome." | 3.73 | Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report. ( Alvir, D; Kondić, L; Matijević, V; Supe, S, 2006) |
| "During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue." | 2.67 | Side effects during long-term treatment with depot antipsychotic medication. ( Cookson, JC, 1991) |
| "Issues regarding the side effects of antipsychotic medication and the possible contribution of the environment to dose requirements led to a two-year controlled dosage study of maintenance antipsychotic medication and familial environment among recently discharged schizophrenic patients." | 2.66 | Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. ( Bartone, P; Carter, M; Cather, R; Cooley, SJ; DiBarry, AL; Hogarty, GE; Madonia, MJ; McEvoy, JP; Munetz, M; Ulrich, RF, 1988) |
| " The evidence available from prospective controlled trials suggests that substantial dosage reduction is feasible for a subgroup of outpatient schizophrenics and that the incidence of abnormal involuntary movements might be reduced by such a strategy." | 2.65 | Low dose medication strategies in the maintenance treatment of schizophrenia. ( Kane, JM, 1983) |
| "Relapse was often characterized by a return of the dame symptoms as the patient had during his first schizophrenic attack." | 2.65 | A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. ( Wistedt, B, 1981) |
| " The results suggest that lower doses of fluphenazine decanoate than those usually used may be effective in preventing psychotic relapse while keeping total cumulative dosage to a minimum." | 2.65 | Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. ( Kane, JM; Klein, DF; Nayak, D; Quitkin, F; Ramos-Lorenzi, JR; Rifkin, A; Sachar, EJ; Saraf, K, 1979) |
| "Relapse was accompanied by a resurgence of specifically schizophrenic symptoms and by an increase in abnormalities described by the relatives." | 2.64 | Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. ( Gaind, R; Hirsch, SR; Rohde, PD; Stevens, BC; Wing, JK, 1973) |
| " In addition, the clinician should consider the dosage schedule of each medication and balance this against the probability of extrapyramidal side effects and noncompliance." | 2.38 | Dose response of prophylactic antipsychotics. ( Brauzer, B; Casey, DE; Davis, JM; Gierl, B; Hassan, M; Kane, JM; Marder, SR; Schooler, N, 1993) |
| "The determinants of relapse have been elusive." | 1.26 | Low serum neuroleptic levels predict relapse in schizophrenic patients. ( Brown, WA; Chisholm, E; Laughren, T; Williams, BW, 1982) |
| "This high rate of relapse is viewed as indicating the need for continued medication in most chronic schizophrenic patients." | 1.26 | Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. ( Aderounmu, AF; Odejide, OA, 1982) |
| "281 newly admitted female schizophrenic patients were treated with high dosage fluphenazine decanoate intramuscularly, starting with 250 mg per injection together with antiparkinsonian and antidepressant drugs." | 1.26 | Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate. ( Nagy, C; Steiner, S, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 72 (76.60) | 18.7374 |
| 1990's | 16 (17.02) | 18.2507 |
| 2000's | 3 (3.19) | 29.6817 |
| 2010's | 3 (3.19) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matar, HE | 1 |
| Almerie, MQ | 1 |
| Sampson, SJ | 1 |
| Hawton, K | 2 |
| Witt, KG | 1 |
| Taylor Salisbury, TL | 1 |
| Arensman, E | 1 |
| Gunnell, D | 1 |
| Hazell, P | 1 |
| Townsend, E | 1 |
| van Heeringen, K | 1 |
| Ruzić, K | 1 |
| Dadić-Hero, E | 1 |
| Knez, R | 1 |
| Medved, P | 1 |
| Petrić, D | 1 |
| Zivković, M | 1 |
| Mihaljević-Peles, A | 1 |
| Sagud, M | 1 |
| Silić, A | 1 |
| Mihanović, M | 1 |
| Supe, S | 1 |
| Matijević, V | 1 |
| Kondić, L | 1 |
| Alvir, D | 1 |
| Hartmann, W | 1 |
| Kind, J | 2 |
| Meyer, JE | 1 |
| Müller, P | 3 |
| Steuber, H | 2 |
| Brown, WA | 2 |
| Laughren, T | 1 |
| Chisholm, E | 1 |
| Williams, BW | 1 |
| Johnson, DA | 6 |
| Pasterski, G | 1 |
| Ludlow, JM | 1 |
| Street, K | 1 |
| Taylor, RD | 1 |
| Kane, JM | 8 |
| Hogarty, GE | 3 |
| Leff, J | 1 |
| Kuipers, L | 1 |
| Berkowitz, R | 1 |
| Eberlein-Fries, R | 1 |
| Sturgeon, D | 1 |
| Rifkin, A | 10 |
| Quitkin, F | 7 |
| Nayak, D | 4 |
| Ramos-Lorenzi, J | 2 |
| Woerner, M | 2 |
| Reardon, G | 2 |
| Sarantakos, S | 1 |
| Schiebel, D | 1 |
| Wistedt, B | 4 |
| Ranta, J | 1 |
| Marder, SR | 4 |
| Van Putten, T | 3 |
| Mintz, J | 5 |
| McKenzie, J | 2 |
| Lebell, M | 2 |
| Faltico, G | 1 |
| May, PR | 2 |
| Marriott, P | 1 |
| Pansa, M | 1 |
| Hiep, A | 1 |
| Palmstierna, T | 1 |
| Mattes, JA | 1 |
| Jørgensen, A | 1 |
| Wiles, D | 1 |
| Levine, J | 3 |
| Schooler, NR | 6 |
| Severe, J | 1 |
| Escobar, J | 1 |
| Gelenberg, A | 1 |
| Mandel, M | 1 |
| Sovner, R | 1 |
| Steinbook, R | 1 |
| Odejide, OA | 1 |
| Aderounmu, AF | 1 |
| Goldberg, SC | 1 |
| Shenoy, RS | 1 |
| Sadler, A | 1 |
| Hamer, R | 1 |
| Ross, B | 1 |
| Steiner, S | 2 |
| Nagy, C | 1 |
| Severe, JB | 3 |
| Brauzer, B | 2 |
| DiMascio, A | 1 |
| Klerman, GL | 1 |
| Tuason, VB | 1 |
| Siris, SG | 3 |
| Bermanzohn, PC | 1 |
| Mason, SE | 1 |
| Shuwall, MA | 1 |
| Inderbitzin, LB | 2 |
| Lewine, RR | 1 |
| Scheller-Gilkey, G | 2 |
| Swofford, CD | 2 |
| Egan, GJ | 1 |
| Gloersen, BA | 1 |
| Vidanagama, BP | 1 |
| Waternaux, C | 1 |
| Steingard, S | 1 |
| Allen, M | 1 |
| Davis, JM | 3 |
| Gierl, B | 1 |
| Schooler, N | 1 |
| Casey, DE | 1 |
| Hassan, M | 1 |
| Wirshing, WC | 1 |
| Johnston-Cronk, K | 1 |
| Liberman, RP | 1 |
| Ware, C | 1 |
| Mistry, H | 1 |
| Hewitt, J | 1 |
| Kingsbury, S | 1 |
| Roberts, D | 1 |
| Weitzel, H | 1 |
| Kasckow, JW | 1 |
| Keith, SJ | 1 |
| Matthews, SM | 1 |
| Bellack, AS | 1 |
| Glick, ID | 1 |
| Hargreaves, WA | 1 |
| Ninan, PT | 1 |
| Frances, A | 1 |
| Jacobs, M | 1 |
| Lieberman, JA | 1 |
| Mance, R | 1 |
| Simpson, GM | 1 |
| Woerner, MG | 1 |
| Heresco-Levy, U | 1 |
| Greenberg, D | 1 |
| Lerer, B | 1 |
| Javitt, DC | 1 |
| Battaglia, J | 1 |
| Wolff, TK | 1 |
| Wagner-Johnson, DS | 1 |
| Rush, AJ | 1 |
| Carmody, TJ | 1 |
| Basco, MR | 1 |
| Gitlin, M | 3 |
| Nuechterlein, K | 1 |
| Subotnik, KL | 1 |
| Ventura, J | 2 |
| Fogelson, DL | 1 |
| Bartzokis, G | 1 |
| Aravagiri, M | 1 |
| Gosenfeld, L | 1 |
| Tsai, CC | 1 |
| Lohrengel, S | 1 |
| Schiff, AA | 1 |
| Kane, J | 4 |
| Ramos-Lorenzi, JR | 2 |
| Klein, DF | 5 |
| Schindler, R | 1 |
| Rabiner, CJ | 1 |
| Goldstein, MJ | 2 |
| Rodnick, EH | 1 |
| Evans, JR | 1 |
| Steinberg, MR | 1 |
| Ulrich, R | 1 |
| Mussare, F | 1 |
| Ferro, P | 1 |
| Herron, E | 1 |
| Saraf, K | 1 |
| Sachar, EJ | 1 |
| Leff, JP | 1 |
| Falloon, I | 2 |
| Watt, DC | 2 |
| Shepherd, M | 2 |
| Arató, M | 1 |
| Erdós, A | 1 |
| Caroli, F | 1 |
| Littre-Poirier, MF | 1 |
| Ginestet, D | 1 |
| Deniker, P | 1 |
| Woggon, B | 1 |
| Angst, J | 1 |
| Margoses, N | 1 |
| Soni, SD | 1 |
| Sampath, G | 1 |
| Shah, A | 1 |
| Krska, J | 1 |
| Nuechterlein, KH | 2 |
| Dawson, ME | 2 |
| Snyder, KS | 2 |
| Yee, CM | 1 |
| Kirkpatrick, B | 1 |
| Carpenter, WT | 1 |
| Maeda, K | 1 |
| Buchanan, RW | 1 |
| Breier, A | 1 |
| Tamminga, CA | 1 |
| Cookson, JC | 1 |
| Gómez Vegas, A | 1 |
| Silmi Moyano, A | 1 |
| Blázquez Izquierdo, J | 1 |
| Corral Rosillo, J | 1 |
| Delgado Martín, JA | 1 |
| Gómez Ruiz, JJ | 1 |
| Prieto Chaparro, L | 1 |
| Salinas Casado, J | 1 |
| Ushakov, IuV | 1 |
| Kravchenko, NE | 1 |
| Hirsch, SR | 4 |
| Jolley, AG | 1 |
| Borenstein, M | 2 |
| Angrist, B | 1 |
| Peselow, E | 1 |
| Rubinstein, M | 1 |
| Wolkin, A | 1 |
| Rotrosen, J | 1 |
| Boza, RA | 1 |
| Milanes, F | 1 |
| Starkey, T | 1 |
| Slater, V | 1 |
| Dominguez, F | 1 |
| Asarnow, RF | 1 |
| Zimmerman, KE | 1 |
| Curson, DA | 2 |
| Platt, SD | 2 |
| Bamber, RW | 2 |
| Barnes, TR | 2 |
| Strahan, A | 2 |
| Sørensen, TT | 1 |
| Sørensen, PS | 1 |
| Kreisman, D | 1 |
| Blumenthal, R | 1 |
| McEvoy, JP | 1 |
| Munetz, M | 1 |
| DiBarry, AL | 1 |
| Bartone, P | 1 |
| Cather, R | 1 |
| Cooley, SJ | 1 |
| Ulrich, RF | 1 |
| Carter, M | 1 |
| Madonia, MJ | 1 |
| Jayaram, G | 1 |
| Coyle, J | 1 |
| Tune, L | 1 |
| Lesser, MS | 1 |
| Kahan, M | 1 |
| Brenner, R | 1 |
| Rappe, S | 1 |
| Fogelson, D | 1 |
| Selander, JM | 1 |
| Miller, WC | 1 |
| Duffy, JC | 1 |
| Reardon, GT | 1 |
| Doddi, SR | 1 |
| Hall, KS | 1 |
| Freeman, H | 1 |
| Carney, MW | 1 |
| Sheffield, BF | 1 |
| Denham, J | 2 |
| Adamson, L | 2 |
| Gaind, R | 1 |
| Rohde, PD | 1 |
| Stevens, BC | 1 |
| Wing, JK | 1 |
| Gardos, G | 1 |
| Friemert, K | 1 |
| Beier, R | 1 |
| Vehreschild, T | 1 |
| Ravaris, CL | 1 |
| Weaver, LA | 1 |
| Brooks, GW | 1 |
| Svestka, J | 1 |
| Náhunek, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics[NCT03376763] | Phase 4 | 201 participants (Actual) | Interventional | 2017-11-21 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
9 reviews available for fluphenazine and Recrudescence
| Article | Year |
|---|---|
Fluphenazine (oral) versus placebo for schizophrenia.
Topics: Administration, Oral; Akathisia, Drug-Induced; Antipsychotic Agents; Fluphenazine; Humans; Placebos; | 2018 |
Pharmacological interventions for self-harm in adults.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fluphenazine; Humans; L | 2015 |
The use of depot neuroleptics: clinical experience in the United States.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Depressive Disorder; Drug Administration Sche | 1984 |
Dose response of prophylactic antipsychotics.
Topics: Administration, Oral; Aftercare; Antipsychotic Agents; Combined Modality Therapy; Delayed-Action Pre | 1993 |
Overview: maintenance therapy in psychiatry: I. Schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation; Female; Fluphenazine; Humans; Male; | 1975 |
Maintenance antipsychotic drugs do prevent relapse: a reply to Tobias and MacDonald.
Topics: Antipsychotic Agents; Chlorpromazine; Chronic Disease; Drug Evaluation; Fluphenazine; Humans; Perphe | 1976 |
Maintenance therapy and schizophrenia.
Topics: Acute Disease; Adult; Ambulatory Care; Antipsychotic Agents; Chlorpromazine; Chronic Disease; Clinic | 1975 |
[Current status of neuroleptic long term treatment of schizophrenia].
Topics: Ambulatory Care; Antiparkinson Agents; Chronic Disease; Delayed-Action Preparations; Flupenthixol; F | 1975 |
Antipsychotic medication: clinical guidelines for maintenance therapy.
Topics: Administration, Oral; Ambulatory Care; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Dise | 1985 |
50 trials available for fluphenazine and Recrudescence
| Article | Year |
|---|---|
Low dose medication strategies in the maintenance treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Re | 1983 |
Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Topics: Antipsychotic Agents; Attitude to Health; Behavior Therapy; Clinical Trials as Topic; Family; Family | 1984 |
Psychosocial relevance and benefit of neuroleptic maintenance: experience in the United Kingdom.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Attitude to Health; Clinical Trials as Topic; Delayed | 1984 |
Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
Topics: Adult; Aftercare; Double-Blind Method; Female; Fluphenazine; Humans; Male; Psychiatric Status Rating | 1982 |
Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
Topics: Adult; Ambulatory Care; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; | 1983 |
Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Depression; Double-Blind Method; Flupenthixo | 1983 |
The use of depot neuroleptics: clinical experience in the United States.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Depressive Disorder; Drug Administration Sche | 1984 |
Costs and benefits of two doses of fluphenazine.
Topics: Adult; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Sch | 1984 |
Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Topics: Adult; Depressive Disorder; Double-Blind Method; Female; Flupenthixol; Fluphenazine; Humans; Male; P | 1983 |
A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency.
Topics: Delayed-Action Preparations; Female; Flupenthixol; Fluphenazine; Humans; Male; Recurrence; Schizophr | 1982 |
Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Delayed-Action Preparations; Dyskinesia, Drug | 1980 |
A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Female; Flu | 1981 |
Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Fluphenazine; Humans; Male; Psychiatric Status | 1980 |
Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial.
Topics: Adult; Antipsychotic Agents; Benztropine; Delayed-Action Preparations; Depressive Disorder; Double-B | 1994 |
A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Topics: Adult; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action Preparations; Double | 1994 |
A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Fe | 1994 |
Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
Topics: Acute Disease; Administration, Oral; Adult; Ambulatory Care; Double-Blind Method; Drug Administratio | 1994 |
Paracetamol self-poisoning. Characteristics, prevention and harm reduction.
Topics: Acetaminophen; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparation | 1996 |
Substance use: a powerful predictor of relapse in schizophrenia.
Topics: Adult; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Dose-Response Relationship, | 1996 |
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
Topics: Adolescent; Adult; Ambulatory Care; Combined Modality Therapy; Delayed-Action Preparations; Dose-Res | 1997 |
Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluph | 1997 |
Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Emergency Treatment; | 1999 |
Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cross-Over Studies; Double-Blind Method; Fluphenazine; Foll | 2001 |
Overview: maintenance therapy in psychiatry: I. Schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation; Female; Fluphenazine; Humans; Male; | 1975 |
[Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication].
Topics: Aftercare; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Fluphenazine; Humans | 1978 |
Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; Hu | 1978 |
Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.
Topics: Acute Disease; Administration, Oral; Aftercare; Chronic Disease; Clinical Trials as Topic; Dyskinesi | 1977 |
Drug and family therapy in the aftercare of acute schizophrenics.
Topics: Acute Disease; Adult; Aftercare; Dose-Response Relationship, Drug; Family Therapy; Female; Fluphenaz | 1978 |
Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.
Topics: Administration, Oral; Adolescent; Adult; Aftercare; Delayed-Action Preparations; Female; Fluphenazin | 1979 |
Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.
Topics: Aftercare; Dose-Response Relationship, Drug; Double-Blind Method; Fluphenazine; Humans; Recurrence; | 1979 |
Maintenance therapy and schizophrenia.
Topics: Acute Disease; Adult; Ambulatory Care; Antipsychotic Agents; Chlorpromazine; Chronic Disease; Clinic | 1975 |
Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data [proceedings].
Topics: Basal Ganglia Diseases; Clinical Trials as Topic; Female; Fluphenazine; Humans; Male; Placebos; Recu | 1977 |
A one-year double-blind comparison of long-acting oral (penfluridol) versus long-acting injectable (fluphenazine decanoate) antipsychotic drugs in multiple-episode schizophrenics.
Topics: Administration, Oral; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Fluphenazine; | 1977 |
A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia.
Topics: Adult; Clinical Trials as Topic; Depression; Female; Fluphenazine; Humans; Male; Pimozide; Recurrenc | 1978 |
[Experience with depot neuroleptics].
Topics: Adolescent; Adult; Clinical Trials as Topic; Delayed-Action Preparations; Drug Evaluation; Drug Ther | 1979 |
Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Fluphenazine; Humans; Recurrence; Schizophren | 1979 |
A pilot study of "low-dose" fluphenazine decanoate in outpatient schizophrenics [proceedings].
Topics: Adult; Ambulatory Care; Clinical Trials as Topic; Female; Fluphenazine; Humans; Male; Pilot Projects | 1979 |
The social outcome of patients in a trial of long-term continuation therapy in schizophrenia: pimozide vs. fluphenazine.
Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Employment; England; Female; Fluph | 1978 |
[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Fluph | 1975 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Side effects during long-term treatment with depot antipsychotic medication.
Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; | 1991 |
The dysphoric syndrome in schizophrenia and its implications for relapse.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Fluphenazine; Fol | 1989 |
Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities.
Topics: Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluphenazine; Humans; Male; Middl | 1988 |
Does short term placebo treatment of chronic schizophrenia produce long term harm?
Topics: Chronic Disease; Clinical Trials as Topic; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Mi | 1986 |
Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view.
Topics: Adolescent; Adult; Attitude; Dose-Response Relationship, Drug; Family; Female; Fluphenazine; Humans; | 1988 |
Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.
Topics: Adult; Dose-Response Relationship, Drug; Emotions; Environment; Family; Female; Fluphenazine; Humans | 1988 |
Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Fluphenazine; Follow-Up Studies; Humans; Recu | 1985 |
Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Chronic Disease; Clinical Trials as Topic; Delayed-Action | 1973 |
Are antipsychotic drugs interchangeable?
Topics: Attitude; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, | 1974 |
Further studies with fluphenazine enanthate: II. Relapse rate in patients deprived of medication.
Topics: Fluphenazine; Humans; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia; Schizophreni | 1967 |
38 other studies available for fluphenazine and Recrudescence
| Article | Year |
|---|---|
Pregnancy and atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Female; Fluphenazine; Human | 2009 |
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Topics: Adult; Alleles; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cytochrome P-450 CYP2D6; Dibenzot | 2010 |
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Drug Therapy, Combination; Early Diag | 2006 |
Neuroleptic drugs and the prevention of relapse in schizophrenia: a workshop report.
Topics: Aggression; Akinetic Mutism; Ambulatory Care; Antipsychotic Agents; Depression; Diagnosis, Different | 1980 |
Low serum neuroleptic levels predict relapse in schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Male; Middle A | 1982 |
The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Female; Flupenthixol; Fl | 1983 |
[What should we recommend for schizophrenic patients: long-term drug prevention or interval treatment?].
Topics: Ambulatory Care; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Administration Sch | 1983 |
Intervals between long acting neuroleptics: outcome and re-admission variables.
Topics: Age Factors; Chronic Disease; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Patient Readmis | 1984 |
Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives.
Topics: Adolescent; Adult; Double-Blind Method; Drug Therapy, Combination; Fluphenazine; Humans; Lithium; Mi | 1984 |
Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Topics: Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Fluphenazine; Humans; Psychiatric | 1982 |
The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics [proceedings].
Topics: Adult; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Recurrence; Schizophrenia | 1981 |
[Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].
Topics: Adolescent; Adult; Aged; Child; Drug Administration Schedule; Fluphenazine; Follow-Up Studies; Human | 1980 |
Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate.
Topics: Age Factors; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Humans; Recurrence; | 1981 |
Maintenance drugs in schizophrenia.
Topics: Administration, Oral; Delayed-Action Preparations; Fluphenazine; Humans; Injections; Penfluridol; Re | 1978 |
[Prevention of relapse in the era of depot neuroleptics and social psychiatry].
Topics: Aftercare; Community Mental Health Services; Community Psychiatry; Delayed-Action Preparations; Fami | 1976 |
Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia.
Topics: Delayed-Action Preparations; Flupenthixol; Fluphenazine; Humans; Recurrence; Schizophrenia; Thioxant | 1979 |
Observations on the dose regime of fluphenazine decanoate in maintenance therapy ofschizophrenia.
Topics: Adult; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1975 |
Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
Topics: Administration, Oral; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Dyskinesia, | 1992 |
Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Topics: Administration, Oral; Adult; Brain; Dopamine; Fluphenazine; Haloperidol; Humans; Male; Prolactin; Ps | 1992 |
[Priapism secondary to phenothiazines].
Topics: Adult; Delayed-Action Preparations; Drainage; Fluphenazine; Humans; Male; Middle Aged; Priapism; Rec | 1991 |
[Clinico-economical aspects of long-term therapy with moditen-depot].
Topics: Cost-Benefit Analysis; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Tolerance | 1990 |
Compliance in the long-term treatment of schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Humans; Patient Compliance; Recurrence; Sc | 1985 |
Amphetamine response and relapse risk after depot neuroleptic discontinuation.
Topics: Adult; Amphetamine; Antipsychotic Agents; Delayed-Action Preparations; Female; Fluphenazine; Humans; | 1985 |
Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
Topics: Adult; Antipsychotic Agents; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Middle Aged; Pat | 1988 |
The significance of depression in the prediction of relapse in chronic schizophrenia.
Topics: Adult; Depressive Disorder; Female; Flupenthixol; Fluphenazine; Humans; Male; Middle Aged; Recurrenc | 1988 |
Continuation and maintenance treatment trials of adjunctive imipramine therapy in patients with postpsychotic depression.
Topics: Benztropine; Depressive Disorder; Drug Therapy, Combination; Fluphenazine; Humans; Imipramine; Psych | 1988 |
[Repeated acute dystonia following administration of metoclopramide and fluphenazine].
Topics: Acute Disease; Adult; Dystonia; Female; Fluphenazine; Humans; Metoclopramide; Recurrence | 1988 |
Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Chronic Disease; Female; Fluphenazine; Humans; Injections, | 1986 |
Dantrolene sodium as a possible prophylactic agent against N.M.S.
Topics: Adult; Dantrolene; Fluphenazine; Humans; Male; Neuroleptic Malignant Syndrome; Recurrence; Schizophr | 1986 |
Expressed emotion, fixed-dose fluphenazine decanoate maintenance, and relapse in recent-onset schizophrenia.
Topics: Adult; Emotions; Family; Female; Fluphenazine; Humans; Male; Recurrence; Schizophrenia; Schizophreni | 1986 |
Prolixin group. Can nursing intervention groups lower recidivism?
Topics: Adult; Aged; Combined Modality Therapy; Delayed-Action Preparations; Fluphenazine; Goals; Hospitaliz | 1985 |
Stability of the postpsychotic depression syndrome.
Topics: Adult; Depressive Disorder; Female; Fluphenazine; Humans; Male; Middle Aged; Outcome and Process Ass | 1986 |
Drug defaulting by patients on long-acting phenothiazines.
Topics: Antipsychotic Agents; Attitude to Health; Comprehensive Health Care; Delayed-Action Preparations; Fl | 1973 |
The long-term maintenance treatment of schizophrenic out-patients with depot flupenthixol.
Topics: Basal Ganglia Diseases; Bipolar Disorder; Catatonia; Depression; Female; Fluphenazine; Hospitalizati | 1973 |
The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients.
Topics: Administration, Oral; Adolescent; Adult; Aftercare; Aged; Chronic Disease; Delayed-Action Preparatio | 1971 |
Long-acting phenothiazines in the prevention of relapse of schizophrenic patients.
Topics: Administration, Oral; Adolescent; Adult; Aftercare; Aged; Chronic Disease; Comprehensive Health Care | 1973 |
[Results of therapy with Lyogen-Depot in schizophrenic diseases].
Topics: Administration, Oral; Chronic Disease; Delayed-Action Preparations; Drug Evaluation; Female; Fluphen | 1974 |
Flupenthixol depot in the maintenance treatment of psychoses.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Butyrophenones; Delayed-Action Preparations; Ethano | 1972 |